97
Elimination
Half-Life
Mechanism of
Action
Major Adverse
Effects
Important Pharmacokinetic
Drug Interactions
13–19 h Inhibits I
Kr
I
Ks
, I
Na
, I
Kur
,
I
to
, I
Ca-L
, I
KAch
Noncompetitive
betablocker
Abdominal pain
Asthenia
Bradycardia
Diarrhea
Nausea and
vomiting
QT prolongation
Rash
TdP
Dronedarone is a substrate
for CYP3A and is a moderate
inhibitor of CYP3A and CYP
2D6
Dronedarone is also a
substrate for, and inhibitor
of, p-gp
Dronedarone may increase
plasma concentrations of:
Dabigatran
Digoxin
Simvastatin
||
Sirolimus
Tacrolimus
Warfarin
e following drugs may
increase plasma dronedarone
concentrations:
Grapefruit juice
e following drugs may
decrease plasma dronedarone
concentrations:
CYP 3A inducers including
St. John's wort, rifampin, and
phenytoin
12–27 h Inhibits I
Na
Atrial flutter
AV block
Dizziness
Dyspnea
Exacerbation of
HFrEF
Headache
Nausea
QT prolongation
VT
Visual
disturbances
Flecainide is a substrate for
CYP 2D6
e following drugs may
increase plasma flecainide
concentrations:
Amiodarone
Duloxetine
Fluoxetine
Paroxetine
